Evidence map›Paper›PMID 42227763›Full record

ReviewJournal of virology2026

Subtype-specific functions of basal IFNλs.

Megan L Stanifer

Abstract readReview
In one paragraph

Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Megan L StaniferDepartment of Molecular Genetics and Microbiology, University of Florida College of Medicine, Gainesville, Florida, USA.ORCID 0000-0002-5606-1297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type III interferons (IFNλs) represent the newest interferon family, comprising four human subtypes (IFNλ1-4) that signal through the tissue-restricted IFNLR1 receptor. While traditionally characterized as antiviral cytokines protecting mucosal barriers, accumulating evidence suggests that IFNλs possess broader physiological roles that remain incompletely understood. A critical gap in our knowledge concerns whether the four IFNλ subtypes function redundantly, or serve distinct biological purposes. Recent discoveries challenge the assumption of functional redundancy among IFNλ subtypes. Emerging data indicate that different subtypes exhibit distinct signaling kinetics, potencies, and downstream effects on epithelial biology. Beyond their established antiviral functions, IFNλs appear to regulate fundamental aspects of epithelial homeostasis, including barrier integrity, cellular differentiation, and tissue architecture. The discovery of constitutive basal IFNλ expression in healthy epithelia-driven by microbiota and endogenous danger signals-suggests that these cytokines continuously shape tissue physiology rather than functioning solely as inducible defense molecules. Understanding subtype-specific IFNλ functions has become increasingly urgent as these cytokines enter clinical development. The tissue-restricted expression of IFNLR1 offers therapeutic advantages over broadly-acting type I interferons, but optimal clinical application requires comprehensive knowledge of how individual subtypes influence both pathogen control and tissue homeostasis. Critical questions remain: Do specific subtypes preferentially regulate barrier function versus antiviral immunity? Can imbalanced subtype expression contribute to epithelial pathology? How do pathogens differentially induce IFNλ subtypes to evade immunity or promote tissue damage? Addressing these questions will illuminate fundamental principles of mucosal immunity and guide rational design of IFNλ-based therapeutics that maximize protection while preserving epithelial health.

Indexed as

InterferonsAnimalsEpithelial CellsHumansInterferon LambdaInterleukinsReceptors, InterferonSignal TransductionIFNLR1 protein, humanInterferon Lambdainterferon-lambda, humanInterferonsInterleukinsReceptors, Interferonbasal gene expressionepithelial cellsIFNλinterferontype III interferon

Identifiers

PMID42227763
PMCPMC13288807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.